Benefit from adrenocorticotrophin in myasthenia gravis.
Twenty-one of 29 patients suffering from myasthenia gravis derived benefit from a short intensive course of adrenocorticotrophin (ACTH). The mean duration of benefit was approximately six months. The best results were obtained in patients with a short history of myasthenia. Transient deterioration during the course of injections was encountered in some cases but necessitated assisted respiration only in patients with severe generalized weakness before treatment.
D000293:Adolescent; D000324:Adrenocorticotropic Hormone / Q000009:adverse effects / Q000627:therapeutic use*; D000328:Adult; D005260:Female; D006801:Humans; D008297:Male; D008659:Metabolic Diseases / Q000139:chemically induced; D008875:Middle Aged; D009157:Myasthenia Gravis / Q000188:drug therapy*; D011188:Potassium / Q000378:metabolism; D012964:Sodium / Q000378:metabolism; D013997:Time Factors
D000324:Adrenocorticotropic Hormone; D012964:Sodium; D011188:Potassium